Видео 30
Просмотров 10 963

Updates in Low Risk MDS with Dr. Max Stahl

53:23

Management of Polycythemia Vera with Dr. Aaron Gerds

56:45

ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni

47:25

Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

1:00:28

Maintenance Therapy in Myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin

52:35

Essential Thrombocythemia with Dr. Raajit Rampal

35:08

Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma

In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space.
Here are the key papers we discussed:
1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): pubmed.ncbi.nlm.nih.gov/34655533/
2. S0777 trial (VRd vs Rd in newly diagnosed myeloma [transplant-ineligible or transplant-deferred]): pubmed.ncbi.nlm.nih.gov/32393732/
3. IMROZ trial (Isatuximab-VRd vs VRd in newly diagnosed transplant-ineligible myeloma): pubmed.ncbi.nlm.nih.gov/38832972/
4. IFM-2020/BENEFIT trial (Isatuximab-VRd ...

Видео

Updates in Low Risk MDS with Dr. Max Stahl

53:23

Updates in Low Risk MDS with Dr. Max Stahl

Просмотров 12128 дней назад

In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteria www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 2. MEDALIST trial: Luspatercept www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0pubmed 3. COMMANDS trial : Lu...

Management of Polycythemia Vera with Dr. Aaron Gerds

56:45

Management of Polycythemia Vera with Dr. Aaron Gerds

Просмотров 225Месяц назад

In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed: 1. MIPS PV scoring system pubmed.ncbi.nlm.nih.gov/31945802/ 2. REVEAL study ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell 3. MAJIC PV study ascopubs.org/doi/10.1200/JCO.22.01935?url_ve...

ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni

47:25

ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni

Просмотров 3742 месяца назад

In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL library.ehaweb.org/eha/2024/eha2024-congress/4136516 2. Epco-P...

Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

1:00:28

Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

Просмотров 3873 месяца назад

In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic. Here are the key studies we discussed: 1. GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers. www.nature.com/articles/s41375-018-0107-z 2. MIPSS70 Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primar...

Maintenance Therapy in Myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin

52:35

Maintenance Therapy in Myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin

Просмотров 5714 месяца назад

In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed: 1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation): pubmed.ncbi.nlm.nih.gov/28742454/ 2. Myeloma XI RCT (lenalidomide vs observation): pubmed.ncbi...

Essential Thrombocythemia with Dr. Raajit Rampal

35:08

Essential Thrombocythemia with Dr. Raajit Rampal

Просмотров 6734 месяца назад

In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes: 1. IPSET (revised) system, risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status: ashpublications.org/blood/article/120/26/5128/30914/Development-and-validation-of-an-International 2. The MIPSS-ET provides points for: · ...

Career Development as a Clinician-Investigator with Dr. Ayalew Tefferi

47:00

Career Development as a Clinician-Investigator with Dr. Ayalew Tefferi

Просмотров 1075 месяцев назад

In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic.

47:00

Career Development as a Clinician-Investigator with Dr. Ayalew Tefferi

Просмотров 1175 месяцев назад

In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic.

Management of Newly Diagnosed AL Amyloidosis

50:18

Management of Newly Diagnosed AL Amyloidosis

Просмотров 2296 месяцев назад

In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic. Here are the key articles discussed: 1. Optimal use of tissue biopsy in AL amyloidosis: pubmed.ncbi.nlm.nih.gov/28271734/ 2. Mayo 2004 staging: pubmed.ncbi.nlm.nih.gov/15365071/ 3. Mayo 2012 staging: www.ncbi.nlm.nih.gov/pmc/articles/PMC3675680/ 4. Renal staging: pubmed....

ASH 2023 Leukemia and Myeloid Neoplasm Recap with Dr. Anand Patel

54:51

ASH 2023 Leukemia and Myeloid Neoplasm Recap with Dr. Anand Patel

Просмотров 1117 месяцев назад

In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed: 1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelo...

GVHD Prophylaxis in Allo-Transplant with Dr. Shernan Holtan

51:51

GVHD Prophylaxis in Allo-Transplant with Dr. Shernan Holtan

Просмотров 2537 месяцев назад

In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota. Here are the key trials we discussed: 1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, a...

ASH 2023 Myeloma Recap with Dr. Ben Derman

1:01:16

ASH 2023 Myeloma Recap with Dr. Ben Derman

Просмотров 1,8 тыс.8 месяцев назад

In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode: First, we will focus on a few abstracts in precursor states, MGUS. 1. New diagnostic criteria for light chain MGUS (IStopMM): ash.confex.com/ash/2023/webprogram/Paper188547.html ash.confex.com/ash/2023/webprogram/Paper182...

ASH 2023 Lymphoma Recap with Dr. Toby Eyre

50:39

ASH 2023 Lymphoma Recap with Dr. Toby Eyre

Просмотров 3958 месяцев назад

In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK. Here are the abstracts that were discussed: Mantle Cell Lymphoma 1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant ...

Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson

1:08:17

Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson

Просмотров 2079 месяцев назад

In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 1. Glofitamab for Relapsed/Refractory DLBCL: pubmed.ncbi.nlm.nih.gov/36507690/ 2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL: pubmed.ncbi.nlm.nih.gov/3145144...